AB0476 The efficacy of immunoadsorption with infliximab theraepy on the modulation of disease activity in patients with severe rheumatoid arthritis

Background Active refractory rheumatoid arthritis (RA) is common in real-world. Patients with active refractory RA usually have poor prognosis. And they respond poorly to a variety of therapies. The arrival of remission or low disease activity (LDA) as soon as possible is an important way to improve their prognosis. We investigated the effectiveness of immunoadsorption therapy, a novel blood purification treatment, as a rapid and sustained disease-modifying therapy for active refractory RA. Objectives To evaluated the efficacy of additional immunoadsorption therapy (2 times) besides infliximab (IFX) ondisease remission in patients with active refractory RA. Methods 90 patients with serve RA were included in this study. 43 patients were treated with basic IFX 3 mg/kg+methotrexate (MTX) therapy, and otherdifferent peri 47 patients, besides of basic therapy, were previous given 2 times additional immunoadsorption therapy. IFX 3 mg/kg was infused at weeks 0, 2, 6, 14, 22 and 30. Age, sex ration, mean disease duration and core index of disease activity in two treatment groups were collected at weeks 0, 2, 6 and 30 weeks to compare the efficacy and safety of combined immunosorbent therapy in the treatment of severe RA. Results The baseline age, sex ration and core indexes of disease activity were comparable between the two treatment groups (p>0.05). After treatment, the core indexes of disease activity of all patients decreased significantly compared with their baseline levels (p Conclusions Additional immunoadsorption therapy can rapid relive the disease activity of serve RA patients, and the remission rate of 30 W was significantly higher than only IFX treatment. However, due to the limited sample size of this study, the efficacy of additional immunoadsorptionneeds further observations. References [1] Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Immunity201721;46(2):183–196. doi:10.1016/j.immuni.2017.02.006 [2] Alam J, Jantan I, Bukhari SNA. Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy. Biomed Pharmacother2017;92:615–633. doi:10.1016/j.biopha.2017.05.055 [3] Boissier MC, Semerano L, Challal S, et al. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J Autoimmun39(3):222–228. doi:10.1016/j.jaut.2012.05.021 [4] Hu H, Luan L, Shu-Chuen L. How Quality of Life as Patient-Reported Outcome Has Been Studied for Rheumatoid Arthritis in Chinese-Speaking Population. Value in Health Regional Issues2015;6:98–102. doi:10.1016/j.vhri.2005.03.001 [5] 5.J Firth, N Snowden, J Ledingham,et, al. The 1st National Clinical audit for Rheumatoid and Early Inflammatory Arthritis: findings and implications for nursing practiceBr J Nurs.2016, 25(11): 613–617. doi:10.12968/bjon.2016.25.11.613 Acknowledgements This study was supported by Natural foundation of Liaoning Province (2015020298), Dalian medical science research project (1712041) Disclosure of Interest None declared